Effectiveness of First-line Therapy for Small Cell Lung Cancer with IO Chemotherapy

被引：0
|
作者：
Grohe, C. [1 ]
机构：
[1] Elk Ev Lungenklin, Klin Pneumol, Berlin, Germany
来源：
PNEUMOLOGIE | 2022年 / 76卷
关键词：
D O I：
10.1055/s-0042-1747799
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Po 249
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [31] Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer
    Levy, B. P.
    Signorovitch, J. E.
    Yang, H.
    Patterson-Lomba, O.
    Xiang, C. Q.
    Parisi, M.
    CURRENT ONCOLOGY, 2019, 26 (03) : E300 - E308
  • [32] Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer
    Mencoboni, M.
    Bergaglio, M.
    Serra, M.
    Ivaldi, G. P.
    Tredici, S.
    Racchi, O.
    Rebella, L.
    Galbusera, V.
    Grosso, M.
    Faravelli, B.
    ANTICANCER RESEARCH, 2007, 27 (6C) : 4425 - 4429
  • [33] Can a single pill replace doublet chemotherapy in first-line therapy of advanced non-small cell lung cancer?
    Bunn, Paul A., Jr.
    CLINICAL CANCER RESEARCH, 2006, 12 (20) : 5919 - 5920
  • [34] Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer
    Hu, Huabin
    She, Longjiang
    Liao, Mengting
    Shi, Yin
    Yao, Linli
    Ding, Dong
    Zhu, Youwen
    Zeng, Shan
    Carbone, David P.
    Huang, Jin
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [35] COST-EFFECTIVENESS ANALYSIS OF TREMELIMUMAB AS FIRST-LINE THERAPY FOR METASTATIC NON-SMALL CELL LUNG CANCER IN JAPAN
    Sakai, R.
    Moriwaki, K.
    Morimoto, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2024, 27 (06) : S150 - S150
  • [36] Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
    Liu, Guoqiang
    Kang, Shuo
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 85 - 91
  • [37] Cost-Effectiveness of the Addition of Bevacizumab to First-Line Chemotherapy With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer
    Parody-Rua, Elizabeth
    Augusto Guevara-Cuellar, Cesar
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 23 : 93 - 98
  • [38] Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer
    Hao, Xuezhi
    Shen, Aizong
    Wu, Bin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [39] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [40] Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China.
    Li, Lingyu
    Wang, Hong
    Li, Wenqian
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345